infliximab_nab
Statistical code for a study of Petr et al.
Science Score: 57.0%
This score indicates how likely this project is to be science-related based on various indicators:
-
✓CITATION.cff file
Found CITATION.cff file -
✓codemeta.json file
Found codemeta.json file -
✓.zenodo.json file
Found .zenodo.json file -
✓DOI references
Found 4 DOI reference(s) in README -
○Academic publication links
-
○Academic email domains
-
○Institutional organization owner
-
○JOSS paper metadata
-
○Scientific vocabulary similarity
Low similarity (4.6%) to scientific vocabulary
Repository
Statistical code for a study of Petr et al.
Basic Info
- Host: GitHub
- Owner: filip-tichanek
- License: other
- Language: HTML
- Default Branch: main
- Size: 27.5 MB
Statistics
- Stars: 0
- Watchers: 1
- Forks: 0
- Open Issues: 0
- Releases: 0
Metadata Files
README.md
Authors and affiliations
1 Institute for Clinical and Experimental Medicine, Prague, Czech Republic
2 Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA
3 Feinberg Cardiovascular and Renal Research Institute, Northwestern University, Chicago, IL, USA
4 Department of Medicine, Carver College of Medicine, University of Iowa, IA, USA
5 Iowa City VA HCS, Iowa City, IA, USA
6 Departments of Medicine, Surgery and Biomedical Sciences, Cedars Sinai Medical Center, Los Angeles, CA, USA
# Co-senior authors, contributed equally
This is a statistical report of the study titled Pretransplant natural antibody levels identify a subset of deceased donor kidney transplant recipients that benefit from infliximab induction that has been published in the American Journal of Transplantation.
When using this code or data, cite the original publication:
V. Petr, F. Tichanek, S.L. Liu, F. Poppelaars, B. Renner, J. Laskowski, S. Purohit, M. Zhao, D. Jalal, P.S. Heeger, J.M. Thurman, Pretransplant natural antibody levels identify a subset of deceased donor kidney transplant recipients that benefit from infliximab induction, American Journal of Transplantation (2025). https://doi.org/10.1016/j.ajt.2025.06.003.
BibTeX entry is provided in a CITATION.bib file
Original GitHub repository: https://github.com/filip-tichanek/infliximab_nAb
Statistical report can be found here
Owner
- Name: filip-tichanek
- Login: filip-tichanek
- Kind: user
- Repositories: 1
- Profile: https://github.com/filip-tichanek
Citation (CITATION.bib)
@article{PETR2025,
title = {Pretransplant natural antibody levels identify a subset of deceased donor kidney transplant recipients that benefit from infliximab induction},
journal = {American Journal of Transplantation},
year = {2025},
issn = {1600-6135},
doi = {https://doi.org/10.1016/j.ajt.2025.06.003},
url = {https://www.sciencedirect.com/science/article/pii/S1600613525002953},
author = {Vojtech Petr and Filip Tichanek and Samuel L. Liu and Felix Poppelaars and Brandon Renner and Jennifer Laskowski and Shrey Purohit and Ming Zhao and Diana Jalal and Peter S. Heeger and Joshua M. Thurman},
keywords = {infliximab, Delayed graft function, natural antibodies, TNF-alpha},
abstract = {Targeting peri-transplant inflammation via TNFα blockade failed to improve kidney transplantation outcomes in the CTOT19 trial that tested infliximab (IFX) induction. As natural antibodies (nAbs) to cardiolipin (CL) and phosphatidylethanolamine (PE) promote graft injury, we hypothesized that CTOT19 outcomes were confounded by nAb levels. Pretransplant plasma aCL and aPE IgM/IgG were measured in 177 CTOT19 subjects and analyzed in relation to delayed graft function (DGF), 2-year estimated glomerular filtration rate (eGFR), and infection. Bayesian modeling with a non-linear treatment-antibody interaction estimated that the IFX effects depend on aCL IgG/IgM and aPE IgG. In patients with low aCL IgG, IFX reduces DGF risk (OR at 5th percentile: 0.13; 95% Credible interval (95%CrI): 0.03 to 0.49) but increases risk at the 95th percentile of aCL IgG levels (OR: 6.24; 95%CrI: 1.38 to 30.32). In patients with aCL IgG below the median, IFX has a positive indirect effect on eGFR via reducing DGF rates. Finally, IFX increases infection risk in patients with low aPE IgG (OR at 5th percentile: 3.12; 95%CrI: 1.11 to 9.08). This analysis identifies a subset of CTOT19 subjects who likely benefit from IFX and suggests pretransplant nAb levels may serve as biomarkers for response to early posttransplant anti-inflammatory therapies.}
}
GitHub Events
Total
- Push event: 15
- Create event: 2
Last Year
- Push event: 15
- Create event: 2